Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCI-2016), a new psychotropic drug with antidepressant activity.
Pharmacological properties of 2-(4-methylamino-butoxy)-diphenylmethane hydrochloride (MCI-2016) were examined in comparison with those of other antidepressants. MCI-2016 significantly antagonized the hypothermia and depression-like syndrome produced by reserpine injection. Furthermore, the drug exhibited such activities as antitetrabenazine and anti-cataleptic actions, and potentiation of the behavioural excitation induced by yohimbine, methamphetamine and L-dopa. MCI-2016 showed a definite suppressive effect on muricidal activity in olfactory bulb removed rats and the long-term isolation-induced fighting in mice without causing apparent motor disturbance. Judging from the effects of the drug on in vitro response to noradrenaline (NA) and serotonin (5-HT), and on p-chloramphetamine-induced hypermotility, it is suggested that MCI-2016 is a selective potentiator of NA presumably due to an inhibition of NA uptake. Anticholinergic and sedative actions of MCI-2016 were considerably weaker than those of amitriptyline and imipramine. Acute toxicity of MCI-2016 was the weakest among the drugs tested. These pharmacological profiles may suggest a potential clinical utility of MCI-2016 as a new psychotropic agent having an antidepressant activity.
D000374:Aggression / Q000187:drug effects; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001559:Benzhydryl Compounds / Q000494:pharmacology*; D002375:Catalepsy / Q000188:drug therapy; D002395:Catecholamines / Q000494:pharmacology; D002415:Cats; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology; D051379:Mice; D010276:Parasympatholytics / Q000494:pharmacology; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors; D013239:Stereotyped Behavior / Q000187:drug effects; D013747:Tetrabenazine / Q000037:antagonists & inhibitors; D015016:Yohimbine / Q000633:toxicity
D000928:Antidepressive Agents; D001559:Benzhydryl Compounds; D002395:Catecholamines; D010276:Parasympatholytics; D015016:Yohimbine; D008694:Methamphetamine; D007980:Levodopa; D012110:Reserpine; C031906:bifemelane; D013747:Tetrabenazine